Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis
 

Like this? Share it with your network

Share

Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis

on

  • 239 views

The field of antibody-drug conjugates (ADC) has seen an explosive growth during the last few years. The number of ADC companies evaluated for preparation of the present report was nearly triple that ...

The field of antibody-drug conjugates (ADC) has seen an explosive growth during the last few years. The number of ADC companies evaluated for preparation of the present report was nearly triple that described in the previous edition of the ADC report in the year 2011. For more information visit: http://goo.gl/gqRRR4

Statistics

Views

Total Views
239
Views on SlideShare
239
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis Presentation Transcript

  • 1. Category : Pharma and Healthcare All logos and Images mentioned on this slide belong to their respective owners. www.MarketResearchReports.com
  • 2. Introduction to Report  Launch Date: January 19, 2014  Number of Pages: 347  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 2,873 Price For Site License: USD 5,746 Price For Global User License: USD 8,620 Delivery Time: Within 24 Hours (During Working Days) www.MarketResearchReports.com
  • 3. About the Report The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The field of antibody-drug conjugates (ADC) has seen an explosive growth during the last few years. The number of ADC companies evaluated for preparation of the present report was nearly triple that described in the previous edition of the ADC report in the year 2011. www.MarketResearchReports.com
  • 4. Research Findings The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years. Spefically, the ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates. As a result of this conjugation technology, the drugantibody ratio may be variable and the product heterogeneous with potential impact on efficacy, safety and pharmacokinetics. www.MarketResearchReports.com
  • 5. Research Findings Continues.. Resistance of cancer cells to currently employed drug payloads of ADCs adds a further parameter for optimization of ADCs. Based on the current state of the art, this report describes the emerging next generation ADC technologies regarding target selection, novel antibody and alternative targeting moiety formats, novel drugs and conjugation systems. The report pays special attention to the commercial relevance and value of these technologies and highlights those picked-up by Big Pharma setting a trend for the first wave of new ADCs based on next generation ADC technologies. www.MarketResearchReports.com
  • 6. Research Findings Continues.. An Addendum lists ADC projects categorized by various variablers and business agreements for collaborations, licensing deals and M&A. Scientific references are provided and non-scientific sources of information are disclosed with hyperlinks. Interestingly, Seattle Genetics abandoned its first generation ADC against CD70 (SGN-75) based on MMAF with a non-cleavable linker in phase I in favor of a next generation ADC with PBD as drug. www.MarketResearchReports.com
  • 7. Benefits Of The Report: Investors Business developers Licensing managers Technology officers R&D Management Business & Competitive Intelligence Analysts Scientific Analysts R&D Planning Portfolio Managers www.MarketResearchReports.com
  • 8. Find in The Report Company profiles of ADC stakeholders ADC drug profiles ADC business agreements ADC pipeline description and analysis Clinical attrition rate of ADCs and reasons for failure ADC target description and analysis Current and future drugs, linkers and conjugation systems Industry preferences for drugs and linkers Alternative targeting moieties New uses of ADCs and immunoconjugates CMOs for manufacturing of ADCs Competitors in development, technology or manufacturing Commercial value of ADC products and technologies www.MarketResearchReports.com
  • 9. Report Coverage 1. Executive Summary 2. Introduction and Overview of the Report 3. Antibody-Drug Conjugates: Pipeline Description and Analysis 4. Stakeholders in Antibody-Drug Conjugates and Immunoconjugates 5. ADC Technologies 6. Business with Antibody-Drug Conjugates 7. ADC & Immunoconjugate Company Profiles 8. References For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners. www.MarketResearchReports.com
  • 10. Company Coverage (Partial List) For more details regarding company coverage and TOC see the last slide All logos and Images mentioned on this slide belong to their respective owners. www.MarketResearchReports.com
  • 11. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ http://www.marketresearchreports.com/idea-center www.MarketResearchReports.com
  • 12. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: http://www.marketresearchreports.com/la-meriepublishing/antibody-drug-conjugates-2014%E2%80%93-business-technology-pipeline-analysis About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : info@marketresearchreports.com Phone: +1 302-703-7787 (USA) +91-8762746600 (India) www.MarketResearchReports.com